0
Editorial |

Antitumor Activity in Metastatic Disease Does Not Predict Efficacy in the Adjuvant Setting

Neil H. Segal, MD, PhD; Leonard B. Saltz, MD
JAMA. 2012;307(13):1431-1432. doi:10.1001/jama.2012.410.
Text Size: A A A
Published online

Extract

The model for drug development in solid tumor malignancies in general, and in colon cancer in particular, has been first to identify a new agent that is effective in patients with refractory disease, and then to use that agent (alone if it is active enough, or in combination with the older agent or regimen if it is not) for patients with metastatic disease and demonstrate improved overall survival, progression-free survival, or both in a randomized trial against the previous standard. That new agent or new agent-containing combination is then used in a randomized trial in the adjuvant setting with the hope of improving the cure rate after definitive surgery. This approach is time-honored and is based on rational expectations, an acceptable apportionment of risk tolerance among patients at various stages of their diseases, and even some positive test results. But what if this strategy is wrong?

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();